The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - 4SC (Inst); Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - WO 2021/177822 A1
Expert Testimony - Freshfields Bruckhaus Deringer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Irene L.M. Reijers
No Relationships to Disclose
 
Robyn P.M. Saw
Honoraria - Merck Sharp & Dohme; Novartis; Qbiotics
Consulting or Advisory Role - Merck Sharp & Dohme; Novartis; Qbiotics
Speakers' Bureau - Bristol-Myers Squibb/Sanofi; Novartis
 
Judith M. Versluis
No Relationships to Disclose
 
Thomas Pennington
No Relationships to Disclose
 
Ellen Kapiteijn
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Ipsen (Inst); Lilly (Inst); Novartis (Inst); Pierre Fabre (Inst)
Research Funding - BMS (Inst); Pierre Fabre (Inst)
 
Astrid Aplonia Maria Van Der Veldt
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Novartis; Roche; Roche
 
Karijn Suijkerbuijk
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst)
Speakers' Bureau - Novartis (Inst); Roche (Inst)
 
Geke Hospers
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Seerave Foundation (Inst)
 
Winan J. van Houdt
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); Sanofi (Inst)
 
W. Martin. C. Klop
No Relationships to Disclose
 
Karolina Sikorska
No Relationships to Disclose
 
Jos A. Van Der Hage
No Relationships to Disclose
 
Dirk J. Grunhagen
No Relationships to Disclose
 
Andrew J Colebatch
No Relationships to Disclose
 
Andrew John Spillane
Honoraria - Lilly
Consulting or Advisory Role - QBiotics
 
Bart A. van de Wiel
Employment - BMSi
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Sanofi (Inst); Sirius Medical (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; Provectus; QBiotics; Regeneron; Skyline Diagnostics